Jennifer Anne Williams Sells 23,688 Shares of GenMark Diagnostics (GNMK) Stock

GenMark Diagnostics (NASDAQ:GNMK) SVP Jennifer Anne Williams sold 23,688 shares of the company’s stock in a transaction dated Friday, May 18th. The shares were sold at an average price of $6.90, for a total transaction of $163,447.20. Following the completion of the sale, the senior vice president now directly owns 197,856 shares in the company, valued at approximately $1,365,206.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Jennifer Anne Williams also recently made the following trade(s):

  • On Monday, February 26th, Jennifer Anne Williams sold 4,911 shares of GenMark Diagnostics stock. The shares were sold at an average price of $4.17, for a total transaction of $20,478.87.
  • On Wednesday, February 21st, Jennifer Anne Williams sold 5,147 shares of GenMark Diagnostics stock. The shares were sold at an average price of $4.40, for a total transaction of $22,646.80.

Shares of GenMark Diagnostics opened at $6.95 on Friday, according to MarketBeat.com. The company has a debt-to-equity ratio of 0.24, a quick ratio of 2.45 and a current ratio of 2.79. GenMark Diagnostics has a 1 year low of $3.63 and a 1 year high of $13.50.

GenMark Diagnostics (NASDAQ:GNMK) last announced its quarterly earnings data on Tuesday, May 1st. The medical equipment provider reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.01. The business had revenue of $20.65 million for the quarter, compared to the consensus estimate of $17.12 million. GenMark Diagnostics had a negative net margin of 97.90% and a negative return on equity of 77.35%. equities research analysts forecast that GenMark Diagnostics will post -0.77 earnings per share for the current fiscal year.

GNMK has been the topic of several recent research reports. BidaskClub raised shares of GenMark Diagnostics from a “hold” rating to a “buy” rating in a report on Tuesday, March 27th. Canaccord Genuity reduced their price target on shares of GenMark Diagnostics from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, February 28th. BTIG Research set a $11.00 price target on shares of GenMark Diagnostics and gave the company a “buy” rating in a report on Wednesday, May 2nd. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price target on shares of GenMark Diagnostics in a report on Tuesday, April 24th. Finally, Zacks Investment Research raised shares of GenMark Diagnostics from a “sell” rating to a “hold” rating in a research note on Thursday, January 25th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. GenMark Diagnostics presently has a consensus rating of “Buy” and an average target price of $10.60.

Several institutional investors and hedge funds have recently made changes to their positions in GNMK. Two Sigma Investments LP lifted its stake in shares of GenMark Diagnostics by 2,266.9% during the fourth quarter. Two Sigma Investments LP now owns 435,887 shares of the medical equipment provider’s stock valued at $1,818,000 after buying an additional 417,471 shares during the period. Bellevue Group AG lifted its stake in shares of GenMark Diagnostics by 53.4% during the first quarter. Bellevue Group AG now owns 1,186,502 shares of the medical equipment provider’s stock valued at $6,455,000 after buying an additional 412,825 shares during the period. Penn Capital Management Co. Inc. lifted its stake in shares of GenMark Diagnostics by 56.4% during the fourth quarter. Penn Capital Management Co. Inc. now owns 543,715 shares of the medical equipment provider’s stock valued at $2,267,000 after buying an additional 196,150 shares during the period. Two Sigma Advisers LP purchased a new position in shares of GenMark Diagnostics during the fourth quarter valued at approximately $618,000. Finally, JPMorgan Chase & Co. lifted its stake in shares of GenMark Diagnostics by 2.8% during the first quarter. JPMorgan Chase & Co. now owns 4,904,257 shares of the medical equipment provider’s stock valued at $26,679,000 after buying an additional 131,504 shares during the period.

About GenMark Diagnostics

GenMark Diagnostics, Inc, a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results.

Insider Buying and Selling by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply